

JTE-607

07/20

ALTERNATE NAMES:	ethyl (2S)-2-[[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]amino]-3- phenylpropanoate;dihydrochloride; L-Phenylalanine, N-(3,5-dichloro-2-hydroxy-4-(2-(4-methyl-1- piperazinyl)ethoxy)benzoyl)-, ethyl ester, dihydrochloride
CATALOG #:	B3064-5 5 mg B3064-25 25 mg
STRUCTURE:	
MOLECULAR FORMULA:	CI C ₂₅ H ₃₃ Cl ₄ N ₃ O ₅
MOLECULAR WEIGHT:	597.36
CAS NUMBER:	188791-09-5
APPEARANCE:	Off White solid
PURITY:	≥98%
SOLUBILITY:	~25 mg/ml in DMSO
DESCRIPTION:	JTE-607 is a multiple cytokine inhibitor. It inhibits cytokine production specifically in human peripheral blood mononuclear cells without causing immunosuppression. It inhibits tumor necrosis factor- α (TNF- α), interleukins IL-1 β , IL-6, IL-8 and IL-10 from LPS-stimulated human PBMCs with IC ₅₀ values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively. It (0.4-0.8 μ M) also inhibits the growth of acute myelogenous leukemia cell lines by inducing apoptosis and cell-cycle arrest.
STORAGE TEMPERATURE:	-20°C. Protect from air. Store under desiccating conditions.
HANDLING:	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
REFERENCES:	 Kakutani, M., Takeuchi, K., Waga, I., et al. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. 48(8):461-8 (1999). Tajima, N., Fukui, K., Uesato, N., et al. JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells. Cancer Sci. 101(3):774-81 (2010).
RELATED PRODUCTS:	
R-7050 (Cat. No. B3063) C87 (Cat. No. B3062) Demethoxycurcumin (Cat. No. B Gabexate mesylate (Cat. No. B (+) Thalidomide (Cat. No. 2020)	3058) ´

(±)-Thalidomide (Cat. No. 2020)

DISCLAIMER:

FOR RESEARCH USE ONLY! Not to be used on humans.